{"id":"NCT00543439","sponsor":"Pfizer","briefTitle":"Study Evaluating Prophylaxis Treatment & Characterizing Efficacy, Safety, & PK Of B-Domain Deleted Recombinant FVIII","officialTitle":"An Open-label Study To Evaluate Prophylaxis Treatment, And To Characterize The Efficacy, Safety, And Pharmacokinetics Of B-domain Deleted Recombinant Factor Viii Albumin Free (Moroctocog Alfa [Af-cc]) In Children With Hemophilia A","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-12","primaryCompletion":"2018-04","completion":"2018-04","firstPosted":"2007-10-15","resultsPosted":"2019-01-11","lastUpdate":"2019-01-11"},"enrollment":66,"design":{"allocation":"RANDOMIZED","model":"CROSSOVER","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Hemophilia A"],"interventions":[{"type":"BIOLOGICAL","name":"Moroctocog alfa (AF-CC)","otherNames":["Xyntha"]},{"type":"BIOLOGICAL","name":"Moroctocog alfa (AF-CC)","otherNames":["Xyntha"]}],"arms":[{"label":"1","type":"EXPERIMENTAL"},{"label":"2","type":"EXPERIMENTAL"}],"summary":"The purpose of this research study is to determine the effectiveness, safety, and pharmacokinetics (PK) of moroctocog alfa (AF-CC) in previously treated subjects, who are younger than 6 years of age, with severe or moderately severe hemophilia A.","primaryOutcome":{"measure":"Mean Annualized Bleed Rate (ABR) by Treatment: On Demand Cohort","timeFrame":"Day 1 up to Month 6 (OD Cohort, OD Therapy, Period 1); Month 7 up to Month 18 (OD Cohort, RP 25 IU/kg, Period 2)","effectByArm":[{"arm":"Moroctocog Alfa (AF-CC), On Demand Cohort: On Demand Therapy","deltaMin":47,"sd":32.2},{"arm":"Moroctocog Alfa (AF-CC), On Demand Cohort: RP Therapy 25 IU/kg","deltaMin":1.5,"sd":2.2}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0020"}]},"eligibility":{"minAge":"6 Months","sex":"MALE","healthyVolunteers":false,"inclusionCount":9,"exclusionCount":6},"locations":{"siteCount":28,"countries":["United States","Argentina","Austria","Colombia","Croatia","Jordan","Mexico","New Zealand","Oman","Peru","Poland","Romania","Turkey (TÃ¼rkiye)"]},"refs":{"pmids":[],"seeAlso":["https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=3082B2-313&StudyName=Study%20Evaluating%20Prophylaxis%20Treatment%20%26%20Characterizing%20Efficacy%2C%20Safety%2C%20%26%20PK%20Of%20B-Domain%20Deleted%20Recombinant%20FVIII"]},"adverseEventsSummary":{"seriousAny":{"events":13,"n":51},"commonTop":["Pyrexia","Upper respiratory tract infection","Cough","Nasopharyngitis","Joint injury"]}}